Furthermore, different milestone papers have demonstrated amyloid-induced Tau-pathology in in vivo animal models, including following (1) crossing or co-expressing of mutant APP/PS1 with mutant Tau in transgenic mice [2, 29, 36, 40, 49] following (2) injection of pre-aggregated Aβ containing extracts derived from AD patients or APP/PS1 transgenic mice [2], or (3) following injection of synthetic pre-aggregated Aβ [13]. The gene discussed is MAPT; the disease is Alzheimer disease.